FDA Issues Guidance on Postapproval Changes for Synthetics

The FDA issued guidance on how sponsors of synthetic drugs should approach post-approval manufacturing process changes — listing examples of low, medium and high risk changes.
Source: International Pharmaceutical Regulatory Monitor